Acura Pharmaceuticals (ACUR): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACUR Stock Summary
- With a market capitalization of $35,798,974, Acura Pharmaceuticals Inc has a greater market value than merely 4.88% of US stocks.
- With a year-over-year growth in debt of -90.41%, Acura Pharmaceuticals Inc's debt growth rate surpasses just 2.59% of about US stocks.
- Revenue growth over the past 12 months for Acura Pharmaceuticals Inc comes in at -52.17%, a number that bests merely 4.41% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Acura Pharmaceuticals Inc, a group of peers worth examining would be NEU, EMAN, OCFT, MOSY, and OPGN.
- ACUR's SEC filings can be seen here. And to visit Acura Pharmaceuticals Inc's official web site, go to www.acurapharm.com.
ACUR Valuation Summary
- In comparison to the median Healthcare stock, ACUR's EV/EBIT ratio is 216.04% lower, now standing at -34.
- ACUR's price/sales ratio has moved up 14 over the prior 243 months.
- ACUR's price/sales ratio has moved up 14 over the prior 243 months.
Below are key valuation metrics over time for ACUR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACUR | 2021-08-31 | 16.1 | 100.5 | -24.5 | -34.0 |
| ACUR | 2021-08-30 | 15.0 | 93.7 | -22.8 | -31.7 |
| ACUR | 2021-08-27 | 16.1 | 100.5 | -24.5 | -34.0 |
| ACUR | 2021-08-26 | 14.7 | 91.9 | -22.4 | -31.1 |
| ACUR | 2021-08-25 | 13.7 | 85.3 | -20.8 | -28.9 |
| ACUR | 2021-08-24 | 15.0 | 93.7 | -22.8 | -31.7 |
ACUR Growth Metrics
- The 2 year price growth rate now stands at -2.78%.
- Its 3 year price growth rate is now at -90.57%.
- Its 4 year cash and equivalents growth rate is now at -63.13%.
The table below shows ACUR's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 2.385 | -1.132 | -1.567 |
| 2021-03-31 | 3.123 | -1.379 | -0.872 |
| 2020-12-31 | 3.57 | -0.719 | -1.208 |
| 2020-09-30 | 4.072 | -0.117 | -0.81 |
| 2020-06-30 | 4.986 | 1.028 | 0.068 |
| 2020-03-31 | 3.681 | 0.128 | -3.581 |
ACUR Stock Price Chart Interactive Chart >
ACUR Price/Volume Stats
| Current price | $0.50 | 52-week high | $0.75 |
| Prev. close | $0.55 | 52-week low | $0.15 |
| Day low | $0.50 | Volume | 1,500 |
| Day high | $0.54 | Avg. volume | 13,257 |
| 50-day MA | $0.58 | Dividend yield | N/A |
| 200-day MA | $0.42 | Market Cap | 11.05M |
Acura Pharmaceuticals (ACUR) Company Bio
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.
Latest ACUR News From Around the Web
Below are the latest news stories about Acura Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACUR as an investment opportunity.
Acura Pharmaceuticals Announces Second Quarter 2021 Financial ResultsPALATINE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and six months ended June 30, 2021. |
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx LTX-03Amendment Extends NDA Acceptance Date Amendment Extends NDA Acceptance Date |
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03Amendment Extends NDA Acceptance DatePALATINE, Ill., July 26, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharma, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to February 28, 2022. LTX-03 (hydrocodone with acetaminophen)Recent reports suggest growing numbers o |
D.R. Horton, Inc. to Release 2021 Third Quarter Earnings on July 22, 2021ARLINGTON, Texas, Jun 18, 2021--D.R. Horton will release financial results for its third quarter ended June 30, 2021 on Thursday, July 22, 2021 before the market opens. |
Acura Pharmaceuticals Announces Conversion of DebtPALATINE, Ill., June 14, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that Abuse Deterrent Pharma, LLC (“AD Pharma”) has converted the entire principle and accrued interest of its Secured Promissory Note (the “Note”) with the Company into shares of the Company’s common stock. Effective with this conversion, the Note is retired and the Company is working with AD Pharma to release their security interest in all the Company’s assets. Under the terms of the Note |
ACUR Price Returns
| 1-mo | -7.41% |
| 3-mo | -26.47% |
| 6-mo | 28.21% |
| 1-year | 85.19% |
| 3-year | 233.33% |
| 5-year | -68.94% |
| YTD | 138.10% |
| 2020 | -8.70% |
| 2019 | 100.17% |
| 2018 | -71.55% |
| 2017 | -47.55% |
| 2016 | -69.20% |
Loading social stream, please wait...